- Oops!Something went wrong.Please try again later.
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617.
Earlier this year, Novartis revealed that the Phase 3 trial linked 177Lu-PSMA-617 to a four-month median improvement in overall survival.
Novartis sought to understand the effect of 177Lu-PSMA-617 on daily activities through secondary endpoints that looked at the patient-reported quality of life and pain.
The endpoints linked the drug to estimated risk reductions in the worsening of health-related quality of life and pain intensity of 54% and 55%, respectively.
The company is ramping up other studies that could enable it to bring 177Lu-PSMA-617 to more prostate cancer patients.
In one study, Novartis is enrolling men who are yet to take taxanes, a class of chemotherapy drugs.
The other ongoing trial could move 177Lu-PSMA-617 into an even line of treatment by testing it in combination with standard of care.
Price Action: NVS stock closed 0.82% lower at $84.38 on Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.